Trial reportMedical oncology (Northwood, London, England)2026
Integrative oncology for young adults with cancer: A prospective pragmatic controlled trial.
Trial report in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research on the impact of integrative oncology (IO) programs on quality of life (QoL) among young adults with cancer is limited. The present study explored the impact of a patient-tailored IO program for young patients undergoing active oncology care. This pragmatic, prospective and preference-controlled study examined patients aged 18-45 referred by oncology healthcare providers to an IO consultation and 6 weekly treatments addressing QoL-related concerns. High adherence to integrative care (high-AIC, vs. low-AIC) was defined as attending ≥ 4 IO sessions, with baseline and 6-week symptoms assessed using ESAS (Edmonton Symptom Assessment Scale); EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire) and MYCAW (Measure Yourself Concerns and Wellbeing) tools. Of 180 patients, 137 (76%) were high-AIC, with similar baseline demographic, cancer-and QoL-related characteristics in both groups. At 6 weeks, high-AIC patients reported greater improvement on ESAS (p = 0.046) and MYCAW (p = 0.008) wellbeing; ESAS nausea (p = 0.027); EORTC dyspnea; and EORTC role functioning (p = 0.031). Significant within-group improvement was observed in older high-AIC patients (aged 40-45, n = 72), as opposed to no improvement in young high-AIC patients (aged 18-39, n = 65) on ESAS fatigue (p = 0.033), anxiety (p = 0.001), and breathing (p = 0.016); and wellbeing on ESAS (p = 0.006) and MYCAW (p < 0.001). Young patients with cancer highly adherent to a 6-week IO program reported significantly improved wellbeing, more significantly among older patients. Further research is needed to explore the impact of IO programs on young patients with cancer, addressing their unique psychological, social, and spiritual needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.